CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
Condition(s):Abnormal Glucose Tolerance; Type 1 DiabetesLast Updated:July 5, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Abnormal Glucose Tolerance; Type 1 DiabetesLast Updated:July 5, 2023Completed
Condition(s):Coronary Heart Disease; Valve Disease, HeartLast Updated:August 26, 2022Completed
Condition(s):Type 1 Diabetes MellitusLast Updated:February 6, 2024Recruiting
Condition(s):Diabetes Mellitus, Type 1Last Updated:May 7, 2020Completed
Condition(s):Diabetes Mellitus, Type 1Last Updated:May 10, 2013Completed
Condition(s):Diabetic NephropathyLast Updated:April 25, 2006Completed
Condition(s):Diabetes Mellitus, Type 1Last Updated:August 2, 2019Completed
Condition(s):Treatment of Type I Diabetes Mellitus.Last Updated:October 23, 2013Unknown status
Condition(s):Cognitive Impairment; Alzheimer Disease; Vascular Cognitive Impairment; Dement; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorder; Cognition DisorderLast Updated:June 6, 2023Recruiting
Condition(s):Type 1 Diabetes MellitusLast Updated:September 12, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.